A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation
Benjamin Heyman1, Michael Choi2, Thomas J Kipps3
1Division of Regenerative Medicine, Department of Medicine, UC San Diego Moores Cancer Center, UC San Diego, La Jolla, California 92093, USA.
Abstract:
Hodgkin lymphoma variant of Richter's transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). In our series of 4 patients, two patients treated with A + AVD for HvRT had durable remissions of 40 and 42 months, while two patients had disease progression and ultimately died. Continued investigation into the optimal management for patients with HvRT is still needed.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Hemodialysis I: Introduction
Graves' Disease I: Introduction


